

## Antibiotic susceptibility testing of bacterial Isolates Associated with Urinary Tract Infection in the northern region of Thi-qar Province.

Karrar Fadhil Hassan<sup>1</sup> , Haydar Khamis Shanan<sup>2</sup>

Email : [karrarfad@vet.shu.edu.iq](mailto:karrarfad@vet.shu.edu.iq)<sup>1</sup>

<sup>1,2</sup> Department of Microbiology, college of Veterinary Medicine, University of Shatra

### Abstract

Urinary tract infections (UTIs) are among the most prevalent infectious diseases, affecting millions worldwide and incurring significant healthcare costs. The study aimed to assess antibiotic resistance to commonly used antibiotics among bacterial pathogens linked to UTIs. Antibiotic susceptibility testing was performed using the disk diffusion method and in accordance with CLSI guidelines (2024). After identification and isolation, only 43 samples were positive for bacterial urinary tract infections (28.7%). The predominant uropathogen was *Escherichia coli* 15 (34.9%), followed by *Klebsiella pneumoniae* 11 (25.6%), *Pseudomonas aeruginosa* 8 (18.6%), *Proteus mirabilis* 5 (11.6%) and *Staphylococcus aureus* 4 (9.3%). *E. coli* isolates showed variable resistance rates to Cefotaxime (60%), Ciprofloxacin (53.3%), Tetracycline (66.7%), Trimethoprim (73.3%) and Trimethoprim/sulfamethoxazole (66.7%). *K. pneumoniae* isolates were high resistant to Ciprofloxacin (63.63%), Tetracycline (100%), Tobramycin (63.63%), Trimethoprim (81.8%) and Trimethoprim/sulfamethoxazole (63.63%). Most of *P. aeruginosa* and *P. mirabilis* were resistance to Trimethoprim (100% for each) and Trimethoprim/sulfamethoxazole (100% and 80%, respectively). All *P. aeruginosa* isolates were resistant to Nitrofurantoin (100%). Isolates of *S. aureus* were significantly resistant to Trimethoprim/sulfamethoxazole (75%), Tobramycin (100%), Erythromycin (100%) and Tetracycline (75%).

**Keywords:** Urinary tract infection, Antibiotic resistance, *Escherichia coli*, *Staphylococcus aureus*

### المخلص

تُعد التهابات المسالك البولية من أكثر الأمراض المعدية شيوعاً، إذ تصيب ملايين الأشخاص حول العالم وتُسبب تكاليف رعاية صحية باهظة. هدفت الدراسة إلى تقييم مقاومة المضادات الحيوية الشائعة الاستخدام بين مسببات الأمراض البكتيرية المرتبطة بالتهابات المسالك البولية. أُجري اختبار حساسية المضادات الحيوية باستخدام طريقة انتشار الأقراص، ووفقاً لإرشادات (CLSI) (2024) بعد تحديد العينات وعزلها، أظهرت 43 عينة فقط نتائج إيجابية لتهابات المسالك البولية البكتيرية (28.7%). وكان المسبب الرئيسي لتهابات المسالك البولية هو الإشريكية القولونية 15 (34.9%)، تليها الكلبسيلا الرئوية 11 (25.6%)، والزانفة الزنجارية 8 (18.6%)، والمتقلبة الرائحة 5 (11.6%)، والمكورات العنقودية الذهبية 4 (9.3%). أظهرت عزلات الإشريكية القولونية معدلات مقاومة متفاوتة لأدوية سيفوتاكسيم (60%)، وسبيروفلوكساسين (53.3%)، وتتراسايكلين (66.7%)، وتريميثوبريم (73.3%)، وتريميثوبريم/سلفاميثوكسازول (66.7%). أما عزلات الكلبسيلا الرئوية فكانت شديدة المقاومة لأدوية سيفروفلوكساسين (63.63%)، وتتراسايكلين (100%)، وتوبراميسين (63.63%)، وتريميثوبريم (81.8%)، وتريميثوبريم/سلفاميثوكسازول (63.63%). أما معظم الزانفة الزنجارية والمتقلبة الرائحة فكانت مقاومة لأدوية تريميثوبريم (100% لكل منهما) وتريميثوبريم/سلفاميثوكسازول (100% و80% على التوالي). وكانت جميع عزلات الزانفة الزنجارية مقاومة للنيتروفورانتوين (100%). أظهرت عزلات المكورات العنقودية الذهبية مقاومة كبيرة لتريميثوبريم / سلفاميثوكسازول (75%)، وتوبراميسين (100%)، إريثروميسين (100%)، وتتراسايكلين (75%).

**الكلمات المفتاحية:** عدوى المسالك البولية، مقاومة المضادات الحيوية، الإشريكية القولونية، المكورات العنقودية الذهبية

### Introduction

Urinary tract infections (UTIs) are common bacterial infections affecting both sexes, with higher prevalence in females [1]. *Escherichia coli* is the primary causative agent in most cases. Diagnosis is based on symptoms and urinalysis, with urine culture recommended for severe or

complicated cases [2]. UTIs are traditionally classified as uncomplicated or complicated, with uncomplicated UTIs occurring in healthy premenopausal women without urinary tract abnormalities [3]. Uncomplicated UTIs are typically easy to treat, while complicated UTIs are more difficult to treat due to the pathogen, the

patient's anatomy or health, and/or the presence of medical devices like stents or urinary catheters [4]. Despite the fact that both men and women can contract UTIs, the disease is usually associated with women, with 50% of them experiencing symptoms throughout the course of their lives [5]. Bacteria can enter and spread throughout the urinary tract by three different routes: the lymphatic, hematogenous, and ascending pathways. The majority of episodes occur through the ascending pathway, while the hematogenous pathway relatively rarely occurs [6]. Ascending route is often facilitated by urinary catheters where bacteria form biofilms and ascend into the bladder [7]. Both the upper and lower urinary tracts may be affected by a UTI. Cystitis, or bladder infection, is a lower UTI, whereas pyelonephritis, or kidney infection, is an upper UTI [8]. The most prevalent type of infection acquired in healthcare settings is healthcare-associated UTIs (HAUTIs) [9]. Traditional treatment involves short-course antimicrobial therapy, but increasing antibiotic resistance poses challenges [10]. Non-antimicrobial options for prevention and management include cranberry products, estrogen therapy for postmenopausal women, and mechanical barrier devices, though evidence for their efficacy varies [11]. Age, diabetes, spinal cord damage, and catheterization are examples of underlying host variables that might worsen UTI and have an impact on its etiology [12]. Studies in Thi-Qar and Basra governorates reveal high antibiotic resistance rates, with *E. coli* showing resistance to commonly prescribed antibiotics like ampicillin and ciprofloxacin in Thi- Qar, and co-trimoxazole and cefotaxime in Basra [13] [14]. While Gram-

negative bacteria demonstrated the highest resistance to Amoxicillin-clavulanate (100%), Piperacillin (100 %), and both Ceftazidime and Nitrofurantoin (86.36 %), Gram-positive isolates exhibited the highest resistance to Amoxicillin-clavulanate (100%), Ampicillin (100%), Oxacillin (100%) in AL-Nasiriyah City [15].

### Materials and method

#### Inclusion and exclusion criteria

Patient who diagnosed with UTIs, exhibiting common symptoms such as dysuria, urinary frequency, urgency, suprapubic pain, or flank pain, were included in this study. Patients with recent antibiotic use for UTI within the past 7–14 days were excluded to avoid false-negative cultures.

#### Samples collection:

A total of 150 Midstream urine samples were collected by clean-catch method from male and female (102 males, 48 females) patients of varying ages ranged between (11-80 year), between September 2024 and February 2025. These samples were obtained from individuals receiving care at hospitals, health centers, and clinics across the northern region of Thi-Qar province (Al Refai, Qalat Suker and Al Naser districts). A structured questionnaire was used to assess all suspected UTI cases. Only one specimen per patient was included.

#### Isolation and identification:

After being cultivated on blood agar and MacConkey agar, the samples were incubated for 24 hours for positive cases and up to 48 hours for negative cases at 37°C. The bacterial isolates were

identified based on colony characteristics and Gram staining, with confirmation through biochemical profiling using biochemical reactions. The main groups of Enterobacteriaceae were differentiated by analyzing their biochemical properties and enzymatic reactions to specific substrates. The IMViC tests include indole, methyl red, Voges-Proskauer, and citrate utilization test were used for this purpose [16]. Additionally, Samples were tested for oxidase activity to differentiate oxidase positive *Neisseria* and *Pseudomonas* spp and oxidase-negative Enterobacteriaceae [17]. Catalase test used to distinguish Gram positive *Staphylococcus* spp from *Streptococcus* spp [18].

#### Antimicrobial susceptibility test:

Patients with no history of antimicrobial drug use for UTIs in the preceding two weeks were included in the study. To assess antibiotic resistance patterns in bacterial isolates associated with urinary tract infections, all isolates underwent antibiogram testing following the Clinical and Laboratory Standards Institute (CLSI, 2024) guidelines [19]. Antimicrobial susceptibility was determined using the Kirby-Bauer disk diffusion method for Amikacin (30 µg), Gentamicin (10 µg), Tobramycin (10 µg), Ciprofloxacin (5 µg), Trimethoprim (5 µg), Trimethoprim / Sulfamethoxazole (25 µg), Tetracycline (30 µg), Cefotaxime (30µg), Cefoxitin (30 µg), Nitrofurantoin (300 µg), Imipenem (10 µg), Clindamycin (2 µg) and Erythromycin (15 µg).

#### Statistical Analysis:

The Statistical Packages of Social Sciences-SPSS (2019) program was used to detect the effect of difference factors in study percentage[20]. Chi-

square test was used in this study .

#### Results and discussion

From 150 samples were taken from patients who diagnosed with Urinary tract infections, bacterial infections were observed in 43 specimens (28.7%). Furthermore 107 (71.3%) of samples exhibited no growth at all, as shown in Figure (1). These results were in line with those of several other research carried out in Iraq. Mohammed Allami et al. reported that 216 out of 830 midstream urine specimens showed positive bacterial cultures (26%) [21]. A study conducted in Baghdad stated that (26.58 %, 63/237) of patients attending Medical City Hospital were positive for bacterial urinary tract infections [22]. In Ebril by Ekrem Kİreççi et al, reported that the prevalence of bacterial urinary tract infections was (58.3 %) [23]. Biochemical reactions and differential media showed only five types of bacteria. The most common isolated pathogen was *E.coli*, accounted for 15 (34.9%), followed by *Klebsiella pneumoniae* (25.6%), *Pseudomonas aeruginosa* (18.6%), *Proteus mirabilis* (11.6%) and *S.aureus* (9.3%) as described in the Table (1). This study observed that Gram-negative bacteria (90.7%) were the leading cause of Urinary tract infections. In comparison, the Gram-positive bacteria recorded (9.3%) of total cases of UTI. This study disagrees with a study conducted by Naji and Awadh. (2022), who reported that Gram-positive bacteria were the predominant pathogen associated with UTI (66.7%), while the prevalence of Gram-negative bacteria was 33.3% [24].

According to residency, the highest rate of UTI cases was in Qalat Suker district 18 (41.9%), while disturbance of UTI cases in Al Refai and

Al-Neser districts was (32.5% and 25.6%) as shown in Table (2). Urinary tract infections was higher in females 26/43 (60.5%), compared to males 17/43 (39.5%) as demonstrated in (Figure 2). Women are more likely to experience UTIs than men because women have shorter urethras than men, as well as short proximity to the anus [4]. The current study agrees with Mazin Saleem Salman who found that females showed the highest prevalence rate of UTIs (77%), while males recorded (23%) of overall cases of UTI [25]. This study revealed that UTI cases were slightly higher in Urban than Rural (accounts for 53.5 and 46.5 respectively) as described in Table (3). The highest rate of bacterial isolates among age groups was in the sixth group aged between (61- 70) years, with 10 (23.25 %) isolates, followed by the group aged (21-30) which recorded 9 isolates (20.93%) . the first age group (11-20), showed the lowest frequency with only 2 patients with UTIs, accounting for (4.65% ), as shown in Table (4). This study agrees with K. Marshall and D. Hale, who reported that UTIs increases with age, as factors like diabetes, kidney stones, stroke, dementia, and bowel and bladder incontinence may predispose elderly people to experience more UTIs [26]. In contrast, it has been observed that younger people who aged between (21-30) exhibited the highest infection rate (35.4% for females and 29.3% for males), followed by the age group 31-40 years [27].

The resistance rates of E.coli against Amikacin, Imipenem, Nitrofurantoin, Tobramycin, Ciprofloxacin, Cefotaxime, Tetracycline, Trimethoprim, Trimethoprim/sulfamethoxazole were 40%, 40%, 40%, 46.7, 53.3%, 60%, 66.7%, 73.3% and

66.7%, respectively (Table 5). This finding was in agreement with data reported by [28], who stated that uropathogenic E. coli showed high resistance to Trimethoprim/sulfamethoxazole (65%), Cefotaxime (75%), and Tetracycline (57%). A study conducted in Baghdad, which found that uropathogenic E.coli isolates were highly resistant to Trimethoprim (82%), and it had a strong correlation with the presence of *dfrA1*-gene [29]. According to Louie Mar Gangcuangco et al. the trimethoprim- sulfamethoxazole resistant isolates of E. coli have shown considerably higher resistance to gentamicin, ampicillin, and fluoroquinolones, in comparison to trimethoprim-sulfamethoxazole-resistant susceptible strains [30]. Since pharmacists and prescriptions are not strictly enforced in the country, and people are free to take medications without a prescription, the high rate of resistance to these antibiotics may be due to self-medication [31].

The high resistance rates of *Klebsiella pneumoniae* isolates to the following antibiotic were: Cefotaxime (54.54%), Imipenem (54.54%), Ciprofloxacin (63.63%), Trimethoprim / Sulfamethoxazole (63.63%), Tobramycin (63.63%), Trimethoprim (81.8%) and Tetracycline (100%), as demonstrated in Table (5). Mohammed et al. (2023) showed that the resistance of *K. pneumoniae* to Cefotaxime was approximately (96.6%), while Ciprofloxacin and Tetracycline were (41.4% and 75.9%, respectively) [32]. A study carried out From November 2021 to of February 2022, reported that the resistance rates of *Klebsiella pneumoniae* against Tetracycline and Trimethoprim / Sulfamethoxazole were 78.1% and 71.5%,

respectively [33], while Shukran A. Mohammed et al. stated that all isolates of *Klebsiella pneumoniae* were resistant to Tetracycline (100%) [34]. The resistance rates of *P. aerogenosa* isolates to Tobramycin, Ciprofloxacin and Imipenem were 75%, 37.5% and 50%, respectively. Nitrofurantoin, Trimethoprim, and Trimethoprim / Sulfamethoxazole had no activity against *Pseudomonas aerogenosa* (100%), as shown in Figure (3). In contrast, a study found that *Pseudomonas aerogenosa* exhibited high resistance to Ciprofloxacin (71.6%) [35]. Our observation disagrees with a study, stated that *Pseudomonas aerogenosa* had a high susceptibility rate to Nitrofurantoin (80%) [36].

*Proteus mirabilis* exhibited high resistance to Ciprofloxacin (60%), Imipenem (80%), Nitrofurantoin (100%), Tetracycline (80%), Trimethoprim (100%) and Trimethoprim/sulfamethoxazole (80%). The current study was close to [37], which reported that all isolates of *Proteus mirabilis* were resistant to Tetracycline and Trimethoprim/sulfamethoxazole (100%). In contrast, a study has been observed that *Proteus mirabilis* had high susceptibility rates against Imipenem and Ciprofloxacin (92% and 75%, respectively) [38]. The susceptibility rates of *S. aureus* isolates to the following antibiotics were: Amikacin (100%), Nitrofurantoin (100%), Ciprofloxacin (50%), Clindamycin (50%), Cefoxitin (50%), and Gentamicin (75%). All isolates of all isolates of *S. aureus* (100%) were resistant to Erythromycin and Tobramycin, while 75% of these isolates were resistant to Tetracycline and Trimethoprim / Sulfamethoxazole, as shown in the Table (6). This

findings were in agreement with a study conducted in Afghanistan found that isolates of *S. aureus* exhibited high resistance rates to Erythromycin (60%) [39]. The mechanisms of resistance to aminoglycosides such as tobramycin in *S. aureus* include reduced uptake, target alterations of the 30S ribosomal subunit, and enzymatic modification of the aminoglycoside drugs [40]. Our finding was consistent with a study, stated that *S. aureus* showed significant susceptibility rate to Nitrofurantoin (88.9%) [41].

#### Conclusion

Bacterial isolates associated with urinary tract infections showed variable resistance to commonly used antibiotics, with high resistance rates of Enterobacteriaceae isolates against Tetracycline, Trimethoprim, and Trimethoprim / Sulfamethoxazole. Nitrofurantoin, Trimethoprim, and Trimethoprim / Sulfamethoxazole were ineffective against *Pseudomonas aerogenosa*. Erythromycin and Tobramycin had no activity against *S. aureus*.

#### References

- [1] R. Kaur and R. Kaur, "Symptoms, risk factors, diagnosis and treatment of urinary tract infections," *Postgrad. Med. J.*, vol. 97, no. 1154, pp. 803–812, 2021, doi: 10.1136/postgradmedj-2020-139090.
- [2] N. S. Sheerin and E. K. Glover, "Urinary tract infection," *Med. (United Kingdom)*, vol. 47, no. 9, pp. 546–550, 2019, doi: 10.1016/j.mpmed.2019.06.008.
- [3] S. Antinori and M. D. Pezzani, "Uncomplicated and complicated urinary tract infections in adults: The infectious diseases's specialist perspective," *Imaging Interv. Urin.*

- Tract Infect. Urosepsis, pp. 17–33, 2018, doi: 10.1007/978-3-319-68276-1\_3.
- [4] L. L. Burrows, “It ’ s uncomplicated : Prevention of urinary tract infections in an era of increasing antibiotic resistance,” pp. 1–9, 2024, doi: 10.1371/journal.ppat.1011930.
- [5] L. K. McLellan and D. A. Hunstad, “Urinary Tract Infection: Pathogenesis and Outlook,” Nov. 01, 2016, Elsevier Ltd. doi: 10.1016/j.molmed.2016.09.003.
- [6] J. D. Sobel, “Bacterial etiologic agents in the pathogenesis of urinary tract infection,” *Med. Clin. North Am.*, vol. 75, no. 2, pp. 253–273, 1991, doi: 10.1016/S0025-7125(16)30452-7.
- [7] L. E. Nicolle, “Urinary Catheter-Associated Infections,” *Infect. Dis. Clin. North Am.*, vol. 26, no. 1, pp. 13–27, 2012, doi: 10.1016/j.idc.2011.09.009.
- [8] S. J. Matthews and J. W. Lancaster, “Urinary Tract Infections in the Elderly Population,” *AJGP*, vol. 9, no. 5, pp. 286–309, 2011, doi: 10.1016/j.amjopharm.2011.07.002.
- [9] M. Medina and E. Castillo-Pino, “An introduction to the epidemiology and burden of urinary tract infections,” 2019, SAGE Publications Inc. doi: 10.1177/1756287219832172.
- [10] A. L. Flores-Mireles, J. N. Walker, M. Caparon, and S. J. Hultgren, “Urinary tract infections: Epidemiology, mechanisms of infection and treatment options,” May 24, 2015, Nature Publishing Group. doi: 10.1038/nrmicro3432.
- [11] L. Rodriguez-Mañas, “Urinary tract infections in the elderly: a review of disease characteristics and current treatment options.,” *Drugs Context*, vol. 9, 2020, doi: 10.7573/dic.2020-4-13.
- [12] A. Ronald, “The etiology of urinary tract infection: Traditional and emerging pathogens,” *Disease-a-Month*, vol. 49, no. 2, pp. 71–82, 2003, doi: 10.1067/mda.2003.8.
- [13] S. Mohammed Mahdi, H. Abdulkareem Yahya, M. kadhim Yasir, and K. Abdul Khadhem Jaber, “Investigation of papA, papC, and papG virulence genes revealed their association with antimicrobial resistance among uropathogenic Escherichia coli strains isolated from patients in Thi-Qar province, Iraq,” vol. 25, pp. 6–10, 2023.
- [14] A. M. Hadi, F. H. Sheri, and A. A. Jaccob, “Urinary Tract Infection Prevalence and Antibiotic Resistance A Retrospective Study in Basra Governorate, Iraq,” *Al Mustansiriyah J. Pharm. Sci.*, vol. 14, no. 2, pp. 129–135, 2014, doi: 10.32947/ajps.v14i2.155.
- [15] M. Jihad and M. Salih, “Microbial Detection and Antibiotic Susceptibility patterns of Clinical Isolates from Women With Urinary Tract Infection in AL-Nasiriyah City/Iraq,” *Univ. Thi-Qar J. Sci.*, vol. 11, no. 1, pp. 45–54, 2024, doi: 10.32792/utq/utjsoci/v11i1.1168.
- [16] A. Jain, O. Jain, and R. Jain, *Basic Techniques in Biochemistry, Microbiology and Molecular Biology ; Principles and Techniques*, vol. 22, no. 4. 2020. doi: 10.3181/00379727-22-113.
- [17] P. Shields and L. Cathcart, “Oxidase Test Protocol,” *Am. Soc. Microbiol. ASM MicrobeLibrary*, no. November 2010, pp. 1–9, 2013.
- [18] J. Cappuccino and C. Welsh, *Microbiology, a laboratory manual*. 2018.
- [19] CLSI, “Performance standards for Antimicrobial susceptibility testing. 34th

Edition,” 2024.

[20] D. George and P. Mallery, “IBM SPSS Statistics 26 Step by Step,” IBM SPSS Stat. 26 Step by Step, 2019, doi: 10.4324/9780429056765.

[21] M. Allami, E. J. Mohammed, F. Alazzawi, and M. Bahreini, “Prevalence and Antibiotic Resistance Pattern of Pathogenic Bacteria Isolated From Urinary Tract Infections in Qal’at Saleh Hospital, Iraq,” *Avicenna J. Clin. Microbiol. Infect.*, vol. 8, no. 4, pp. 117–122, 2021, doi: 10.34172/ajcmi.2021.22.

[22] F. A. S. Al-Gasha’a, S. M. Al-Baker, J. M. Obiad, and F. A. Alrobiai, “Prevalence of urinary tract infections and associated risk factors among patients attending medical city hospital in Baghdad City, Iraq,” *Rev. Bras. Gest. e Desenv. Reg.*, vol. 16, no. 2, pp. 77–84, 2020, doi: 10.3844/ajidsp.2020.77.84.

[23] E. Kİreççi, D. Sleman, and D. Ahmed, “Identification of the bacterial types that cause urinary tract infection and antimicrobial susceptibility in Erbil ,” vol. 3, no. 1, pp. 11–14, 2015.

[24] S. A. Naji and H. A. Awadh, “A Study of Urinary Tract Infections Prevalence, Antibiotics Resistance, and Biofilm Formation Capability of the Bacterial Causal Agents,” vol. 28, no. 1, pp. 82–88, 2023.

[25] M. Saleem Salman, “Antibiotic Resistance of Bacteria Isolated in Urinary Tract Infections,” *J Contemp Med Sci*, vol. 10, no. 2, pp. 163–166, 2024.

[26] K. Marshall and D. Hale, “Urinary tract infection in older adults,” *Aging health*, vol. 9, no. 5, pp. 519–528, 2013, doi: 10.2217/ahe.13.38.

[27] S. Isma’il, “Prevalence of Urinary Tract Infection among Age Groups in Bauchi

Metropolis , Nigeria,” vol. 10, no. 2, pp. 2019–2022, 2021, doi: 10.21275/ART2020227.

[28] Nuha Abd Al.rheem Saad, R. H. Hussein, and N. M. M. Al-Shakir, “Antibiogram Pattern of Uropathogenic Escherichia Coli in Baghdad Province, Iraq,” *J. Tech.*, vol. 4, no. 33, pp. 134–138, 2022, doi: 10.51173/jt.v4i33.729.

[29] R. K. Mohammed and A. A. Ibrahim, “Distribution of dfrA1 and catI antibiotic resistance genes in uropathogenic Escherichia coli isolated from teens pregnant women in Iraq,” *Iraqi J. Sci.*, vol. 63, no. 8, pp. 3340–3353, 2022, doi: 10.24996/ijs.2022.63.8.9.

[30] Q. Louie et al., “Prevalence and risk factors for trimethoprim– sulfamethoxazole-resistant Escherichia coli among women with acute uncomplicated urinary tract infection in a developing country,” *Int. J. Infect. Dis.*, pp. 1–6, 2015, doi: 10.1016/j.ijid.2015.02.022.

[31] A. D. Abed and T. Y. Mutter, “Relationship between antimicrobial resistance and virulence factors in uropathogenic Escherichia coli isolates from Ramadi, Iraq: phenotype and genotype identification,” *Afr. Health Sci.*, vol. 23, no. 3, pp. 486–496, 2023, doi: 10.4314/ahs.v23i3.56.

[32] A. N. Mohammed, D. F. Al-Rawi, and H. K. Buniya, “Evaluation of Antibiotic Resistance of Klebsiella Pneumoniae Isolated from Patients in Hospitals in Iraq,” *Acta Microbiol. Bulg.*, vol. 39, no. 4, pp. 411–417, 2023, doi: 10.59393/amb23390407.

[33] F. H. Omar and A. H. Ibrahim, “THE PREVALENCE OF INTEGRON CLASS I AND II AMONG MULTI-DRUG RESISTANCE PRODUCING KLEBSIELLA pneumonia,” *Iraqi J. Agric. Sci.*, vol. 54, no. 3, pp. 619–629, 2023,

doi: 10.36103/ijas.v54i3.1775.

[34] S. A. H. Mohammed, N. B. Mahdi, and H. S. Akbar, "Sensitivity of Klebsiella Pneumoniae Bacteria Isolated from the Urine of Patients with Urinary Tract Infections in Kirkuk City/ Iraq," *J. Prev. Diagnosis Manag. Hum. Dis.*, no. 44, pp. 1–9, 2024, doi: 10.55529/jpdmhd.44.1.9.

[35] Z. M. M. Alkhulaifi and K. A. S. Mohammed, "Prevalence and molecular analysis of antibiotic resistance of Pseudomonas aeruginosa isolated from clinical and environmental specimens in Basra ," vol. 15, no. 1, pp. 45–54, 2023.

[36] R. H. Raheema, S. H. Hadi, and Z. A. G. Chabuck, "Study of some virulence genes from uropathogenic Klebsiella pneumoniae and Pseudomonas aeruginosa isolated in Wasit Province, Iraq," *Med. J. Babylon*, vol. 21, no. 1, pp. 207–213, 2024, doi: 10.4103/MJBL.MJBL\_1100\_23.

[37] A. A. Alhusayni et al., "Antibiotic Susceptibility Profile of Bacterial Uropathogens

in Al-Shomali General Hospital, Babylon, Iraq," 2022, doi: 10.4103/jpdtm.jpdtm.

[38] B. H. Abdullah, S. S. Ismael, and N. A. Qasim, "Antimicrobial Susceptibility of Proteus mirabilis Isolated from Urinary Tract Infections in Duhok City, Iraq, Using VITEK2 System," *Eur. J. Med. Heal. Res.*, vol. 2, no. 4, pp. 75–79, 2024, doi: 10.59324/ejmhr.2024.2(4).09.

[39] H. M. Naimi, H. Rasekh, A. Z. Noori, and M. A. Bahaduri, "Determination of antimicrobial susceptibility patterns in Staphylococcus aureus strains recovered from patients at two main health facilities in Kabul ," pp. 1–7, 2017, doi: 10.1186/s12879-017-2844-4.

[40] M. Vestergaard, D. Frees, and H. Ingmer, "Antibiotic Resistance and the MRSA Problem," vol. 7, no. 2, pp. 1–23, 2019, doi: 10.1128/microbiolspec.GPP3-0057-2018.Correspondence.

[41] A. M. Radhi and S. M. Al Mayahie, "Resistance of Uropathogenic Staphylococci to Commonly Used Antimicrobials for Treatment of Urinary Tract Infections," pp. 208–213, 2025.




Figure 1: Positive versus negative bacterial culture.




Figure 2: Distribution of UTI patients according to sex.

Table (1): Frequency of isolated pathogens associated with UTIs.

Bacterial isolates	Frequency	
	No.	%
<i>Escherichia coli</i>	15	34.9
<i>Klebsiella pneumonia</i>	11	25.6
<i>Pseudomonas aeruginosa</i>	8	18.6
<i>Proteus mirabilis</i>	5	11.6
<i>Staphylococcus aureus</i>	4	9.3

( $P \leq 0.01$ ).

**Table (2):** Disturbance of UTI according to residency.

Residency	Positive Culture		Total	
	No.	%	No.	%
Al-Neser	11	25.6	50	33.33
AL-Refai	14	32.5	50	33.33
Qalat suker	18	41.9	50	33.33
<b>Total</b>	43	28.7	150	100%

( $P \leq 0.05$ ).

**Table (3):** Disturbance of UTI cases according to habitation

Habitation	Positive Culture		Total	
	No.	%	No.	%
Rural	20	46.5	87	58.00
Urban	23	53.5	63	42.00
<b>Total</b>	43	28.7	150	100

( $P \leq 0.05$ ).

**Table (4):** Distribution of UTI patients according to age.


Age groups	Positive cultures		Total	
	No.	%	No.	%
11-20	2	4.65	37	24.67
21-30	9	20.93	29	19.33
31-40	5	11.63	23	15.33
41-50	6	13.95	16	10.67
51-60	7	16.28	18	12
61-70	10	23.26	19	12.67
> 70	4	9.30	8	5.33
<b>Total</b>	43	28.7	150	100

( $P \leq 0.05$ ).

**Table 5:** Antibiotic susceptibility test for *Enterobacteriaceae*.

List	<i>E.coli</i> No.(%)			<i>K.pneumoniae</i> No.(%)			<i>P. mirabilis</i> No.(%)		
	S	I	R	S	I	R	S	I	R
<b>AK</b>	7(46.7)	2(13.3)	6(40)	5(45.45)	1(9.1)	5(45.45)	3(60)	1(20)	1(20)
<b>CTX</b>	5(33.3)	1(6.7)	9(60)	3(27.3)	2(18.2)	6(54.54)	3(60)	0(0)	2(40)
<b>Fox</b>	8(53.3)	3(20)	4(26.7)	6(54.54)	1(9)	4(36.46)	3(60)	1(20)	1(20)
<b>Cip</b>	6(40)	1(6.7)	8(53.3)	4(36.4)	0(0)	7(63.6)	1(20)	1(20)	3(60)
<b>CN</b>	6(40)	2(13.3)	7(46.7)	5(45.45)	1(9)	5(45.45)	1(20)	2(40)	2(40)
<b>IMI</b>	8(53.3)	1(6.7)	6(40)	3(27.3)	2(18.2)	6(54.54)	0(0)	1(20)	4(80)
<b>F</b>	7(46.7)	2(13.3)	6(40)	7(63.63)	1(9)	3(27.3)	0(0)	0(0)	5(100)
<b>TE</b>	4(26.6)	1(6.7)	10(66.7)	0(0)	0(0)	11(100)	0(0)	1(20)	4(80)
<b>Tob</b>	6(40)	2(13.3)	7(46.7)	2(18.2)	2(18.2)	7(63.63)	3(60)	2(40)	0(0)
<b>TM</b>	3(20)	1(6.7)	11(73.3)	1(9)	1(9)	9(81.8)	0(0)	0(0)	5(100)
<b>SXT</b>	4(26.7)	1(6.7)	10(66.7)	3(27.3)	1(9)	7(63.63)	0(0)	1(20)	4(80)
(P≤0.05).									

No.(%): Number(percentage), S: Sensitive, I: Intermediate, R: Resistant, AK: Amikacin, CTX: Cefotaxime, Fox: Cefoxitin, Cip: Ciprofloxacin, CN: Gentamicin, IMI: Imipenem, F: Nitrofurantoin, TE: Tetracycline, Tob: Tobramycin, TM: Trimethoprim, SXT: Trimethoprim / Sulfamethoxazole. P: p. value.



**Figure 3:** antibiotic resistance rates for *P. aeruginosa*.

SXT: Trimethoprim / Sulfamethoxazole, TM: Trimethoprim, TOB: Tobramycin, F: Nitrofurantoin, IMI: Imipenem, CIP: Ciprofloxacin

**Table (6):** Antibiotic susceptibility test for *S. aureus*.

Antibiotics list	<i>S. aureus</i> No.(%)		
	Sensitive	Intermediate	Resistant
Amikacin	4 (100)	0(0)	0(0)
Cefoxitin	2(50)	0(0)	2(50)
Ciprofloxacin	2(50)	0(0)	2(50)
Clindamycin	2(50)	1(25)	1(25)
Erythromycin	0(0)	0(0)	4(100)
Gentamicin	3(75)	0(0)	1(25)
Nitrofurantoin	4(100)	0(0)	0(0)
Tetracycline	1(25)	0(0)	3(75)
Tobramycin	0(0)	0(0)	4(100)
Trimethoprim / Sulfamethoxazole	1(25)	0(0)	3(75)
(P≤0.05).			

No.(%): Number(percentage), P: p. value.